In the full episode, I cover: -The state of evidence for alleged geroprotective effects of GLP-1 receptor agonists, SGLT2 inhibitors, methylene blue, and telomere-lengthening supplements -Risks and benefits associated with low-dose aspirin for cardiovascular disease (CVD) prevention -Evidence regarding optimal protein intake for maximizing muscle mass, and whether follistatin gene therapy might have promise for further increasing muscle gains -How to apply evidence-based reasoning to separate science from speculation in longevity research -More This AMA episode (Ep
Low Starting Dose A common research starting point is a low daily amount
Over time, regular IV glutathione may help even skin tone and reduce hyperpigmentation
Successful client representation in West Virginia Successful legal representation is a result of years of study and years of practice in and out of the courtroom
Estimated lifetime Cardiovascular, Kidney, and mortality benefits of combination treatment with SGLT2 Inhibitors, GLP-1 receptor Agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria